Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Towa Pharmaceutical Developing Lipitor Generic Version OD Tablets
November 9, 2011
- Nihon Chouzai Planning to Open 150-200 Stores a Year: President Mitsuhara
November 9, 2011
- CMIC Reports Increases in Sales and Profits Driven by CRO Business
November 8, 2011
- Nichi-Iko to Change Company Structure to Strengthen Sales of Generic Drugs
November 8, 2011
- Kaken to Enhance Detailing Activities for GPs Aiming at Sales Expansion for Lipidil, Generics
November 8, 2011
- Towa Pharmaceutical’s New Business Plan is “Groundwork for Future Progress”
November 8, 2011
- Suzuken President Ota Says Wholesale Business Recovery Crucial
November 8, 2011
- Towa Apr-Sep Earnings Limited on Break in Impact of Premium Revision
November 8, 2011
- Intellim Ties Up with SMO Iberica, Aiming to Enter US Market in 2012
November 8, 2011
- Pfizer Japan Applies for Additional Indication for Sutent for pNET Designated as Orphan Disease
November 8, 2011
- Prices Should Remain Stable in 2nd-Half: Pres. Ishiguro of Alfresa HD
November 8, 2011
- Kyorin HD: Both Sales, Profits Remain Virtually Unchanged
November 8, 2011
- Eli Lilly, Amylin to Terminate Collaboration in Field of Diabetes
November 8, 2011
- Kobayashi Pharm. to Create 3 Subsidiaries in Southeast Asia
November 8, 2011
- Takeda Establishes New Positions in R&D, Global Sales
November 7, 2011
- Takeda Reinstates Request for Probe into Transfer Pricing Taxation
November 7, 2011
- Takeda: Sales, Profits Down due to Strong Yen, Double-digit Decreases in Sales of Actos in Apr-Sep
November 7, 2011
- Suzuken Reports Largest Interim Operating Loss From Drug Wholesale Business
November 7, 2011
- Operating Profits Down 70% in Wholesale Business: Alfresa HD
November 7, 2011
- 8 of 10 Leading Drug Makers Report Declines in 1st-Half Sales
November 7, 2011
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…